<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VES</journal-id>
<journal-id journal-id-type="hwp">spves</journal-id>
<journal-id journal-id-type="nlm-ta">Vasc Endovascular Surg</journal-id>
<journal-title>Vascular and Endovascular Surgery</journal-title>
<issn pub-type="ppub">1538-5744</issn>
<issn pub-type="epub">1938-9116</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1538574413485646</article-id>
<article-id pub-id-type="publisher-id">10.1177_1538574413485646</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Effect of Balloon-Occluded Transvenous Obliteration of Gastric Varices and Gastrorenal Shunts on the Hepatic Synthetic Function</article-title>
<subtitle>A Comparison Between Child-Pugh and Model for End-Stage Liver Disease Scores</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Saad</surname>
<given-names>Wael E.A.</given-names>
</name>
<degrees>MBBCh</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
<xref ref-type="corresp" rid="corresp1-1538574413485646"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wagner</surname>
<given-names>Cynthia (Cindy)</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1538574413485646">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Osaimi</surname>
<given-names>Abdulla</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1538574413485646">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bliebel</surname>
<given-names>Wissam</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1538574413485646">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lippert</surname>
<given-names>Allison</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davies</surname>
<given-names>Mark G.</given-names>
</name>
<degrees>MD, PhD, MBA</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sabri</surname>
<given-names>Saher S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turba</surname>
<given-names>Ulku C.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>Alan H.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Angle</surname>
<given-names>John (Fritz)</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Caldwell</surname>
<given-names>Stephen</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413485646">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1538574413485646">
<label>1</label>Division of Vascular Interventional Radiology, Department of Radiology &amp; Medical Imaging, University of Virginia Health System, Charlottesville, VA, USA</aff>
<aff id="aff2-1538574413485646">
<label>2</label>Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA</aff>
<aff id="aff3-1538574413485646">
<label>3</label>Division of Gastroenterology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA</aff>
<author-notes>
<corresp id="corresp1-1538574413485646">Wael E.A. Saad, Department of Radiology, University of Virginia Health System, 1215 Lee Street, PO Box 800170, Charlottesville, VA 22908, USA. Email: <email>wspikes@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>4</issue>
<fpage>281</fpage>
<lpage>287</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<!--CL content="<italic>Vascular and Endovascular Surgery XX&#x00028;X&#x00029;</italic>"-->
<!--CL content="<italic>Saad et al</italic>"-->
<abstract>
<sec>
<title>Purpose:</title>
<p>To evaluate the effect of balloon-occluded transvenous obliteration (BRTO) on the model for end-stage liver disease (MELD) and the Child-Pugh (C-P) score and their individual components.</p>
</sec>
<sec>
<title>Methods:</title>
<p>A retrospective review of patients undergoing only BRTO without transjugular intrahepatic portosystemic shunt was performed (08, 2007 to 06, 2010). Pre- and post-BRTO MELD and C-P scores were calculated. The post-BRTO MELD and C-P score samplings were categorized as (1) immediate (within 14 days), (2) early (14-90 days), and (3) delayed (90-180 days) post-BRTO. The C-P and MELD scores and their individual components before and after (various sample intervals) were compared.</p>
</sec>
<sec>
<title>Results:</title>
<p>A total of 29 consecutive successful BRTO procedures were found and assessed. In all, 26 had immediate post-BRTO sampling (average 1.8 days after BRTO), 13 (57%) had an early post-BRTO sampling (average 47 days from BRTO), and 10 (38%) had a delayed post-BRTO sampling (average 121 days from BRTO). The bilirubin rises significantly (<italic>P</italic> = .007) within days after BRTO, but synthetic function improves significantly between 1.5 and 4.0 months post-BRTO (international normalized ration: <italic>P</italic> = .02, bilirubin: <italic>P</italic> = .027, and albumin: <italic>P</italic> = .012). However, 31% (N = 8/ 26) of the patients had worsening ascites with or without hydrothorax. The MELD score significantly improved circa 4 months post-BRTO (from 14.1 to 10.7, <italic>P</italic> = .0008). However, the C-P score did not change significantly (from 7.6 to 6.7, <italic>P</italic> = .063).</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>The BRTO has a positive effect on the hepatic synthetic function. However, there is a high incidence of post-BRTO ascites (31% of the patients). As a result, the MELD score appears to be a more sensitive gauge for hepatic synthetic function compared to the C-P score for patients undergoing BRTO.</p>
</sec>
</abstract>
<kwd-group>
<kwd>MELD score</kwd>
<kwd>BRTO</kwd>
<kwd>gastric varices</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1538574413485646">
<title>Introduction</title>
<p>The model for end-stage liver disease (MELD) score is a computation of the serum total bilirubin, creatinine, and international normalized ratio (INR) and is, unlike the Child-Pugh (C-P) score, independent of the presence or absence of ascites.<sup>
<xref ref-type="bibr" rid="bibr1-1538574413485646">1</xref>,<xref ref-type="bibr" rid="bibr2-1538574413485646">2</xref>
</sup> The MELD score is an indicator of hepatic function (hepatic reserve) and is an established objective predictor of postprocedural outcome in cirrhotics for hepatic and nonhepatic surgeries and minimal invasive procedures including transjugular intrahepatic portosystemic shunt (TIPS) procedures for which it was originally developed.<sup>
<xref ref-type="bibr" rid="bibr3-1538574413485646">3</xref>
<xref ref-type="bibr" rid="bibr4-1538574413485646"/>
<xref ref-type="bibr" rid="bibr5-1538574413485646"/>
<xref ref-type="bibr" rid="bibr6-1538574413485646"/>
<xref ref-type="bibr" rid="bibr7-1538574413485646"/>
<xref ref-type="bibr" rid="bibr8-1538574413485646"/>
<xref ref-type="bibr" rid="bibr9-1538574413485646"/>–<xref ref-type="bibr" rid="bibr10-1538574413485646">10</xref>
</sup>
</p>
<p>Balloon-occluded transvenous obliteration (BRTO) of gastric varices is a procedure that involves the transvenous sclerosis of gastric varices via a spontaneous gastrorenal shunt.<sup>
<xref ref-type="bibr" rid="bibr11-1538574413485646">11</xref>
<xref ref-type="bibr" rid="bibr12-1538574413485646"/>
<xref ref-type="bibr" rid="bibr13-1538574413485646"/>
<xref ref-type="bibr" rid="bibr14-1538574413485646"/>
<xref ref-type="bibr" rid="bibr15-1538574413485646"/>
<xref ref-type="bibr" rid="bibr16-1538574413485646"/>
<xref ref-type="bibr" rid="bibr17-1538574413485646"/>–<xref ref-type="bibr" rid="bibr18-1538574413485646">18</xref>
</sup> A consequence of the BRTO procedure is the occlusion (sclerosis) of this spontaneous gastrorenal shunt.<sup>
<xref ref-type="bibr" rid="bibr11-1538574413485646">11</xref>
<xref ref-type="bibr" rid="bibr12-1538574413485646"/>
<xref ref-type="bibr" rid="bibr13-1538574413485646"/>–<xref ref-type="bibr" rid="bibr14-1538574413485646">14</xref>
</sup> The TIPS is known to increase the MELD score, because the newly established shunt functionally diverts blood flow away from the liver.<sup>
<xref ref-type="bibr" rid="bibr3-1538574413485646">3</xref>
<xref ref-type="bibr" rid="bibr4-1538574413485646"/>–<xref ref-type="bibr" rid="bibr5-1538574413485646">5</xref>,<xref ref-type="bibr" rid="bibr19-1538574413485646">19</xref>
</sup> Conversely, BRTO is closure of a spontaneous hepatofugal shunt, potentially diverting blood flow toward the liver.<sup>
<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>
<xref ref-type="bibr" rid="bibr21-1538574413485646"/>
<xref ref-type="bibr" rid="bibr22-1538574413485646"/>
<xref ref-type="bibr" rid="bibr23-1538574413485646"/>–<xref ref-type="bibr" rid="bibr24-1538574413485646">24</xref>
</sup> Thus, BRTO has been known to cause splenomegaly, aggravation of esophageal varices, ascites, and hydrothorax. It is not known whether this is solely portal pressure related or whether there is a liver dysfunction element to these complications (particularly ascites and hydrothorax).<sup>
<xref ref-type="bibr" rid="bibr22-1538574413485646">22</xref>
<xref ref-type="bibr" rid="bibr23-1538574413485646"/>
<xref ref-type="bibr" rid="bibr24-1538574413485646"/>
<xref ref-type="bibr" rid="bibr25-1538574413485646"/>
<xref ref-type="bibr" rid="bibr26-1538574413485646"/>
<xref ref-type="bibr" rid="bibr27-1538574413485646"/>–<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>
</sup> Change in hepatic function can be evaluated utilizing either the C-P or the MELD score; however, the presence of ascites may alter the C-P score with no effect on MELD.<sup>
<xref ref-type="bibr" rid="bibr1-1538574413485646">1</xref>–<xref ref-type="bibr" rid="bibr2-1538574413485646">2</xref>,<xref ref-type="bibr" rid="bibr10-1538574413485646">10</xref>
</sup>
</p>
<p>In the literature, hepatic function post-BRTO has been assessed only by the C-P score.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>
</sup> It is controversial whether the C-P score remains unchanged or improves after BRTO.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>
</sup> However, the majority of authors conclude that if the C-P score improves initially in the first 6 to 9 months after BRTO, it then returns to pre-BRTO baseline levels.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>
</sup> Thus, BRTO (unlike TIPS) preserves hepatic function in the long term.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>
</sup>
</p>
<p>The aim of this study is to evaluate the effect of BRTO on the MELD score, the C-P score, and their components including laboratory values and the presence and absence of ascites/hydrothorax. A secondary aim is to evaluate whether the MELD score is a more sensitive gauge of post-BRTO hepatic reserve.</p>
</sec>
<sec id="section2-1538574413485646" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1538574413485646">
<title>Study Design</title>
<p>This is a retrospective study of consecutive patients undergoing BRTO for gastric varices from August 2007 to December 2010 (3 years). Patients with a prior TIPS or undergoing a combined BRTO and TIPS procedure were excluded from the study. Technically failed BRTO procedures as well as patients without any laboratory follow-up were excluded from the study. Institutional internal review approval was obtained by categorizing the study as secondary use of preexisting anonymous data.</p>
</sec>
<sec id="section4-1538574413485646">
<title>The BRTO Procedure</title>
<p>The BRTO procedure was performed in the standard transrenal approach from a jugular or femoral access utilizing standard catheter techniques.<sup>
<xref ref-type="bibr" rid="bibr11-1538574413485646">11</xref>
<xref ref-type="bibr" rid="bibr12-1538574413485646"/>
<xref ref-type="bibr" rid="bibr13-1538574413485646"/>
<xref ref-type="bibr" rid="bibr14-1538574413485646"/>
<xref ref-type="bibr" rid="bibr15-1538574413485646"/>
<xref ref-type="bibr" rid="bibr16-1538574413485646"/>
<xref ref-type="bibr" rid="bibr17-1538574413485646"/>–<xref ref-type="bibr" rid="bibr18-1538574413485646">18</xref>
</sup> Occlusion of the gastrorenal shunt by balloon-occlusion catheters was followed by placement of a coaxial microcatheter in the gastric varicies. The sclerosant utilized was 3% Sotradecol (sodium tetradecyl sulfate [STS]; Angiodynamics, Inc, Queensbury, New York) as mixed 1 part Lipiodol, 2 parts 3% Sotradecol, and 3 parts air.<sup>
<xref ref-type="bibr" rid="bibr30-1538574413485646">30</xref>
</sup> Occlusion catheters were left inflated and in position for 4 to 36 hours and then deflated.<sup>
<xref ref-type="bibr" rid="bibr30-1538574413485646">30</xref>
</sup> Technical success of the BRTO procedure was considered when the gastrorenal shunt is successfully cannulated, balloon-occluded, and the sclerosant completely fills the gastric variceal system (gastric varices and gastrorenal shunt) in its entirety. Proof of entire filling the gastric variceal system was by intraprocedural fluoroscopy and cone-beam rotational computer tomography (CT). Hemodynamic success (obliteration rate) was determined by a routine (all patients receive it) endoscopic ultrasound with Doppler capabilities within 48 hours of the BRTO procedure. Residual (patent) variceal pockets (considered hemodynamic failures, even if partial) were managed with endoscopic-guided cyanoacrylate injection/sclerosis.</p>
</sec>
<sec id="section5-1538574413485646">
<title>The MELD Score and C-P Score Sampling and Definitions</title>
<p>The pre- and post-BRTO MELD score and the MELD components (total bilirubin, serum creatinine, and INR) were noted. Similarly, the pre- and post-BRTO C-P score and its components (encephalopathy, ascites, serum albumin, total bilirubin, and INR). The time lapse before and after the BRTO procedure when the MELD score, C-P score, and their components were sampled was noted. Some variability was evident due to a lack of standardized follow-up intervals (retrospective study).</p>
<p>The post-BRTO MELD was categorized as (1) an immediate (as close as possible to the BRTO procedure and up to 14 days post-BRTO), (2) an early (15-89 days post-BRTO), and (3) a delayed (90-180 days post-BRTO) post-BRTO MELD. Similarly, the post-BRTO C-P score was also categorized within the same time brackets. The average sample dates differed from the MELD score compared to the C-P score due to heterogeneous laboratory sampling and physical examination dates.</p>
</sec>
<sec id="section6-1538574413485646">
<title>Statistical Analysis</title>
<p>All demographic values, MELD score values, C-P score values, and MELD/C-P score component values are presented as mean, median, and range with standard deviation. Similarly, the sampling dates pre- and post-BRTO were expressed as mean, median, and range with standard deviation. Comparison between all pre- and post-BRTO values was by Wilcoxon matched-pairs signed-rank test. A <italic>P</italic> value of less than .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section7-1538574413485646">
<title>Results</title>
<p>A total of 40 consecutive patients underwent BRTO procedures in the 3-year study period. In all, 19 were female and 21 were male with a mean age of 59 years (range 17-73). In all, 8 patients had nonalcoholic steatohepatosis, 8 had alcohol and hepatitis C cirrhosis, 6 had hepatitis C cirrhosis only, 6 had cryptogenic cirrhosis, 5 had alcohol-related cirrhosis, 2 had autoimmune hepatitis, and 5 had other miscellaneous cases of portal hypertension.</p>
<p>The technical success of BRTO was 97% (N = 38/40). The 2 BRTO technical failures were excluded from the study. The intent to treat (technical failures included) hemodynamic (obliterative) success rate was 88% (N = 35/40), and all 3 technically successful, but hemodynamically unsuccessful (partial obliteration) patients received endoscopic-guided cyanoacrylate sclerosis/injection of the residual (patent) variceal pockets. An additional 9 (23% of patients, N = 9/40) patients had a history of TIPS (N = 6) or underwent a combined TIPS-BRTO procedure (N = 3). These were also excluded. An additional 3 patients were referred from outside institutions and had no laboratory follow-up. The remaining 26 patients (90%, N = 26 of 29 of technically successful BRTO procedures without presence of TIPS) were included in the study for the pre- and post-BRTO MELD score, C-P score, and MELD/C-P components evaluation.</p>
<p>All 26 patients included had an index bleed within 30 days prior to the BRTO procedure, and all were hemodynamically stable without active bleeding at the time of the procedure. None of the 26 patients included had prior treatments (BRTO was the first treatment of gastric varices), and the ones with prior TIPS or TIPS at the same time as BRTO (N = 9) were originally excluded (see above). None of the patients included (N = 26) had moderate (not clinically detectable: asymptomatic and not found on physical examination) or severe (clinically detectable and receiving paracentesis or thoracentesis) prior to the BRTO-procedure.</p>
<p>All 26 patients had pre- and immediate post-BRTO sampling of the MELD score and the C-P score. In all, 13 (50% of patients, N = 13 of 26) patients had an early (14-89 days post-BRTO) MELD score sampling, and 10 (38% of patients, N = 10 of 26) patients had a late (90-180 days post-BRTO) MELD score sampling. Also, 13 (50% of patients, N = 13 of 26) patients had an early (14-89 days post-BRTO) C-P score sampling, and 10 (38% of patients, N = 10 of 26) patients had a late (90-180 days post-BRTO) C-P score sampling. Comparing the patient sampling between those sampled for the MELD score and the C-P score, the patients were the same. However, the time of the data samplings was sometimes different. Part of the reason why 3 patients were not followed up in the early and late post-BRTO period was that they died within 30 days of the BRTO procedure. The baseline MELD score of these 3 patients was a mean of 14.7 (range: 14-16). This is slightly higher than the baseline MELD score of the overall population (mean: 12, range: 7-30). None of these 3 mortalities were due to hepatic failures (2 unexplained without hepatic failure and 1 probably died of cardiac reasons—arrhythmias).</p>
<p>The pre-BRTO MELD sampling occurred at a median of 1.0 ± 3.1 days (mean: 1.8, range: 0-14 days) before the BRTO procedure. The immediate post-BRTO MELD sampling occurred at a median of 1.0 ± 1.1 days (mean: 1.3, range: 1-5 days) after the BRTO procedure. The early post-BRTO MELD sampling occurred at a median of 41 ± 23 days (mean: 47, range: 16-85 days) after the BRTO procedure. The delayed post-BRTO MELD sampling occurred at a median of 111 ± 32 days (mean: 121, range: 90-166 days) after the BRTO procedure.</p>
<p>The pre-BRTO C-P sampling occurred at a median of 1.0 ± 3.1 days (mean: 1.8, range: 0-14 days) before the BRTO procedure. The immediate post-BRTO C-P sampling occurred at a median of 1.0 ± 1.1 days (mean: 1.3, range: 1-5 days) after the BRTO procedure. The early post-BRTO C-P sampling occurred at a median of 39 ± 23 days (mean: 45, range: 16-85 days) after the BRTO procedure. The delayed post-BRTO C-P sampling occurred at a median of 127 ± 32 days (mean: 124, range: 90-166 days) after the BRTO procedure.</p>
<p>The comparative results of the MELD score and the C-P score and their components are displayed in <xref ref-type="table" rid="table1-1538574413485646">Tables 1</xref> and <xref ref-type="table" rid="table2-1538574413485646">2</xref>, respectively. Post-BRTO new-onset or worsening ascites occurred in 8 (31%, N = 8 of 26) patients of those evaluated for post-BRTO MELD and C-P scores. Two of these patients with ascites also had new-onset hydrothorax (7.7%, N = 2 of 26) and were symptomatic. Of the remaining 6 patients with ascites, 3 had mild-to-moderate asymptomatic ascites detected by imaging, and 3 had clinically symptomatic ascites requiring paracentesis (N = 2) and paracentesis with eventually (2 years after BRTO) a TIPS (N = 1). Conversely, 2 (7.7%, N = 2 of 26) patients who had mild ascites (image-based diagnosis, not clinically detected) before the BRTO procedure had their ascites resolved post-BRTO with an improved C-P score and MELD score of 8 to 6 and 14 to 13, respectively, in 1 patient and an improved C-P score and MELD score of 8 to 6 and 12 to 10, respectively, in other patient. There were no incidents of encephalopathy before or after the BRTO procedures. None of the 26 included patients had post-BRTO variceal bleeding.</p>
<table-wrap id="table1-1538574413485646" position="float">
<label>Table 1.</label>
<caption>
<p>Pre-BRTO and Post-BRTO MELD Score Comparison.</p>
</caption>
<graphic alternate-form-of="table1-1538574413485646" xlink:href="10.1177_1538574413485646-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">MELD Score and Components</th>
<th colspan="4">Pre-BRTO MELD (Mean Sample: 1.8 Days Pre-BRTO)</th>
<th colspan="4">Immediate Post-BRTO MELD (Mean Sample: 1.3 Days Post-BRTO)</th>
<th rowspan="2">
<italic>P</italic> Value</th>
</tr>
<tr>
<th>Median</th>
<th>Mean</th>
<th>SD</th>
<th>Range</th>
<th>Median</th>
<th>Mean</th>
<th>SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine</td>
<td>0.80</td>
<td>1.04</td>
<td>0.83</td>
<td>0.5-4.8</td>
<td>0.80</td>
<td>1.01</td>
<td>0.74</td>
<td>0.5-4.3</td>
<td>.391</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>1.55</td>
<td>1.75</td>
<td>1.03</td>
<td>0.4-4.5</td>
<td>1.75</td>
<td>2.14</td>
<td>1.44</td>
<td>0.6-6.4</td>
<td>.007<sup>a</sup>
</td>
</tr>
<tr>
<td>INR</td>
<td>1.40</td>
<td>1.41</td>
<td>0.20</td>
<td>1.0-1.8</td>
<td>1.40</td>
<td>1.44</td>
<td>0.23</td>
<td>1.0-2.0</td>
<td>.074</td>
</tr>
<tr>
<td>MELD</td>
<td>13.0</td>
<td>13.2</td>
<td>4.3</td>
<td>7-30</td>
<td>13.0</td>
<td>13.7</td>
<td>4.6</td>
<td>7-30</td>
<td>.119</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="4">Pre-BRTO MELD (Mean Sample: 1.8 Days Pre-BRTO)</td>
<td align="center" colspan="4">Early Post-BRTO MELD (Mean Sample: 47 Days Post-BRTO)</td>
<td>
</td>
</tr>
<tr>
<td>MELD Score and Components</td>
<td align="right">Median</td>
<td align="right">Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="center">Median</td>
<td align="center">Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="right">
<italic>P</italic> Value</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.80</td>
<td>1.15</td>
<td>1.15</td>
<td>0.5-4.8</td>
<td>0.80</td>
<td>1.00</td>
<td>0.38</td>
<td>0.6-1.8</td>
<td>.322</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>1.4</td>
<td>1.8</td>
<td>1.26</td>
<td>0.4-4.5</td>
<td>1.0</td>
<td>1.6</td>
<td>1.74</td>
<td>0.3-6.6</td>
<td>.414</td>
</tr>
<tr>
<td>INR</td>
<td>1.40</td>
<td>1.39</td>
<td>0.20</td>
<td>1.0-1.7</td>
<td>1.30</td>
<td>1.34</td>
<td>0.31</td>
<td>1.0-2.2</td>
<td>.206</td>
</tr>
<tr>
<td>MELD</td>
<td>12.0</td>
<td>13.5</td>
<td>5.5</td>
<td>9-30</td>
<td>11.0</td>
<td>11.8</td>
<td>5.6</td>
<td>6-24</td>
<td>.278</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="4">Pre-BRTO MELD (Mean Sample: 1.8 Days Pre-BRTO)</td>
<td align="center" colspan="4">Late Post-BRTO MELD (Mean Sample: 121 Days Post-BRTO)</td>
<td>
</td>
</tr>
<tr>
<td>MELD Score and Components</td>
<td align="center">Median</td>
<td align="center">Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="center">Median</td>
<td align="center">Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="right">
<italic>P </italic>Value</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.75</td>
<td>1.23</td>
<td>1.31</td>
<td>0.5-4.8</td>
<td>0.80</td>
<td>0.93</td>
<td>0.32</td>
<td>0.7-1.7</td>
<td>.383</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>1.25</td>
<td>1.82</td>
<td>1.36</td>
<td>0.4-4.5</td>
<td>1.05</td>
<td>1.29</td>
<td>0.77</td>
<td>0.6-2.9</td>
<td>.027<sup>a</sup>
</td>
</tr>
<tr>
<td>INR</td>
<td>1.45</td>
<td>1.41</td>
<td>0.21</td>
<td>1.0-1.7</td>
<td>1.30</td>
<td>1.27</td>
<td>0.17</td>
<td>1.0-1.5</td>
<td>.020<sup>a</sup>
</td>
</tr>
<tr>
<td>MELD</td>
<td>12.5</td>
<td>14.1</td>
<td>6.2</td>
<td>9-30</td>
<td>10.0</td>
<td>10.7</td>
<td>2.9</td>
<td>7-15</td>
<td>.008<sup>a</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1538574413485646">
<p>Abbreviations: MELD, model for end-stage liver disease; BRTO, balloon-occluded transvenous obliteration; SD, standard deviation; INR, international normalized ratio.</p>
</fn>
<fn id="table-fn2-1538574413485646">
<p>
<sup>a</sup> <italic>P</italic> &lt; .05 considered statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1538574413485646" position="float">
<label>Table 2.</label>
<caption>
<p>Pre-BRTO and Post-BRTO Child-Pugh Score Comparison.</p>
</caption>
<graphic alternate-form-of="table2-1538574413485646" xlink:href="10.1177_1538574413485646-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Child-Pugh Score and Components</th>
<th colspan="4">Pre-BRTO Child-Pugh (Mean Sample: 1.8 Days Pre-BRTO)</th>
<th colspan="4">Immediate Post-BRTO Child-Pugh (Mean Sample: 1.3 Days Post-BRTO)</th>
<th align="right" rowspan="2">
<italic>P </italic>Value</th>
</tr>
<tr>
<th align="right">Median</th>
<th align="right">Mean</th>
<th align="center">SD</th>
<th align="center">Range</th>
<th align="center">Median</th>
<th align="right">Mean</th>
<th align="center">SD</th>
<th align="center">Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilirubin</td>
<td>1.55</td>
<td>1.75</td>
<td>1.03</td>
<td>0.4-4.5</td>
<td>1.75</td>
<td>2.14</td>
<td>1.44</td>
<td>0.6-6.4</td>
<td>.007<sup>a</sup>
</td>
</tr>
<tr>
<td>INR</td>
<td>1.40</td>
<td>1.41</td>
<td>0.20</td>
<td>1.0-1.8</td>
<td>1.40</td>
<td>1.44</td>
<td>0.23</td>
<td>1.0-2.0</td>
<td>.074</td>
</tr>
<tr>
<td>Albumin</td>
<td>2.85</td>
<td>2.82</td>
<td>0.78</td>
<td>1.1-4.5</td>
<td>2.85</td>
<td>2.90</td>
<td>0.70</td>
<td>1.5-4.1</td>
<td>.701</td>
</tr>
<tr>
<td>Child-Pugh</td>
<td>7.0</td>
<td>7.2</td>
<td>1.58</td>
<td>5-11</td>
<td>6.5</td>
<td>7.3</td>
<td>1.83</td>
<td>5-11</td>
<td>.625</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="4">Pre-BRTO Child-Pugh (Mean Sample: 1.8 Days Pre-BRTO)</td>
<td align="center" colspan="4">Early Post-BRTO Child-Pugh (Mean Sample: 47 Days Post-BRTO)</td>
<td>
</td>
</tr>
<tr>
<td>Child-Pugh Score and Components</td>
<td align="center">Median</td>
<td>Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="center">Median</td>
<td align="center">Mean</td>
<td align="center">SD</td>
<td>Range</td>
<td align="right">
<italic>P </italic>Value</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>1.25</td>
<td>1.80</td>
<td>1.31</td>
<td>0.4-4.5</td>
<td>1.05</td>
<td>1.69</td>
<td>1.80</td>
<td>0.3-6.6</td>
<td>.414</td>
</tr>
<tr>
<td>INR</td>
<td>1.4</td>
<td>1.4</td>
<td>0.2</td>
<td>1.0-1.7</td>
<td>1.3</td>
<td>1.3</td>
<td>0.3</td>
<td>1.0-2.2</td>
<td>.569</td>
</tr>
<tr>
<td>Albumin</td>
<td>2.55</td>
<td>2.58</td>
<td>0.79</td>
<td>1.1-3.9</td>
<td>3.50</td>
<td>3.35</td>
<td>0.61</td>
<td>1.9-4.0</td>
<td>.003<sup>a</sup>
</td>
</tr>
<tr>
<td>Child-Pugh</td>
<td>7.5</td>
<td>7.3</td>
<td>1.72</td>
<td>5-11</td>
<td>6.0</td>
<td>6.7</td>
<td>1.83</td>
<td>5-11</td>
<td>.098</td>
</tr>
<tr>
<td>
</td>
<td align="center" colspan="4">Pre-BRTO Child-Pugh (Mean Sample: 1.8 Days Pre-BRTO)</td>
<td align="center" colspan="4">Late Post-BRTO Child-Pugh (Mean Sample: 121 Days Post-BRTO)</td>
<td>
</td>
</tr>
<tr>
<td>Child-Pugh Score and Components</td>
<td align="right">Median</td>
<td align="right">Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="center">Median</td>
<td align="center">Mean</td>
<td align="center">SD</td>
<td align="center">Range</td>
<td align="center">
<italic>P </italic>Value</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>1.10</td>
<td>1.82</td>
<td>1.44</td>
<td>0.4-4.5</td>
<td>1.00</td>
<td>1.31</td>
<td>0.82</td>
<td>0.6-2.9</td>
<td>.055</td>
</tr>
<tr>
<td>INR</td>
<td>1.45</td>
<td>1.41</td>
<td>0.21</td>
<td>1.0-1.7</td>
<td>1.30</td>
<td>1.27</td>
<td>0.17</td>
<td>1.0-1.5</td>
<td>.020<sup>a</sup>
</td>
</tr>
<tr>
<td>Albumin</td>
<td>2.70</td>
<td>2.64</td>
<td>0.58</td>
<td>1.8-3.7</td>
<td>3.40</td>
<td>3.44</td>
<td>0.83</td>
<td>2.2-4.8</td>
<td>.012<sup>a</sup>
</td>
</tr>
<tr>
<td>Child-Pugh</td>
<td>8.0</td>
<td>7.6</td>
<td>1.8</td>
<td>5-11</td>
<td>7.0</td>
<td>6.7</td>
<td>1.5</td>
<td>5-9</td>
<td>.063</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1538574413485646">
<p>Abbreviations: MELD, model for end-stage liver disease; BRTO, balloon-occluded transvenous obliteration; SD, standard deviation; INR, international normalized ratio.</p>
</fn>
<fn id="table-fn4-1538574413485646">
<p>
<sup>a</sup> <italic>P</italic> &lt; .05 considered statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-1538574413485646">
<title>Discussion</title>
<p>Most prior studies have shown or discussed transient improvement, if not the preservation, of the hepatic function after BRTO.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>
</sup> However, ascites has been described by several studies in 0% to 7% of patients who had undergone a BRTO procedure, with up to 2.6% of patients having massive ascites and/or ascites refractory to medical therapy.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr25-1538574413485646">25</xref>,<xref ref-type="bibr" rid="bibr26-1538574413485646">26</xref>,<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>
</sup> When including trace ascites detected by CT after BRTO, 45% of the patients have ascites.<sup>
<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>
</sup> Similarly, hydrothorax (pleural effusion) has been described in 0% to 8% of the patients who have undergone a BRTO procedure with up to 5.8% of the patients having hydrothorax, which is refractory to medical therapy.<sup>
<xref ref-type="bibr" rid="bibr24-1538574413485646">24</xref>,<xref ref-type="bibr" rid="bibr27-1538574413485646">27</xref>,<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>
</sup> These 2 complications may be related to portal pressure or hepatic dysfunction. The majority of these transudative complications are transient in the early post-BRTO period (within 30-60 days after BRTO).<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>
<xref ref-type="bibr" rid="bibr24-1538574413485646"/>
<xref ref-type="bibr" rid="bibr25-1538574413485646"/>
<xref ref-type="bibr" rid="bibr26-1538574413485646"/>
<xref ref-type="bibr" rid="bibr27-1538574413485646"/>–<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>
</sup> In addition, prior studies have reported significant hepatic function deterioration in the early post-BRTO period due to hepatic failure (within 30 days) in 2.9% to 6.1% of the patients with a 30-day mortality, due to hepatic failure, reported in up to 4.8% of the patients.<sup>
<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>,<xref ref-type="bibr" rid="bibr31-1538574413485646">31</xref>,<xref ref-type="bibr" rid="bibr32-1538574413485646">32</xref>
</sup> The value of the MELD score in the first 3 months post-BRTO is that it enables the evaluation of hepatic function independent of ascites being one of the scoring components (unlike the C-P score).<sup>
<xref ref-type="bibr" rid="bibr1-1538574413485646">1</xref>,<xref ref-type="bibr" rid="bibr2-1538574413485646">2</xref>
</sup> The worsening transudative complications in the presence of improved synthetic function suggests (demonstrated in this study) that these transudative complications are probably portal pressure driven (transudative complications post-BRTO have an oncotic pathogenesis) and not related to hepatocyte dysfunction.</p>
<p>This study shows that BRTO has a positive effect on the hepatic reserve, particularly the synthetic function of the liver, from 1.5 to 4.0 months post-BRTO (<xref ref-type="table" rid="table1-1538574413485646">Tables 1</xref> and <xref ref-type="table" rid="table2-1538574413485646">2</xref>). Both the total serum bilirubin and the INR drop below baseline significantly, and the albumin increases significantly between 1.5 and 4.0 months (<xref ref-type="table" rid="table1-1538574413485646">Tables 1</xref> and <xref ref-type="table" rid="table2-1538574413485646">2</xref>). However, BRTO has little effect over the serum creatinine within the first 4 months post-BRTO (<xref ref-type="table" rid="table1-1538574413485646">Tables 1</xref> and <xref ref-type="table" rid="table2-1538574413485646">2</xref>). The improvement in hepatic synthetic indices in part explains the relative greater improvement in the MELD score compared to the C-P score, while the increased incidence of new-onset or worsening ascites and/or hydrothorax (31% of patients in this study) and the relatively stable creatinine offset the gain in INR, bilirubin, and albumin and result in less change in the C-P score.</p>
<p>On the other hand, it should be noted that the total serum bilirubin has an initial increase in the value in the immediate (within days) post-BRTO period, which was statistically significant (<italic>P</italic> = .007) but not to the extent of increasing the MELD or C-P scores (<xref ref-type="table" rid="table1-1538574413485646">Tables 1</xref> and <xref ref-type="table" rid="table2-1538574413485646">2</xref>). We can only speculate why there is an early spike in the post-BRTO bilirubin. First, the total bilirubin (conjugated and unconjugated) may be high due to an actual spike in the unconjugated bilirubin as a result of hemolysis due to the effect of STS (3% Sotradecol). Second, the rise in bilirubin may be due to peripheral embolization of the intrahepatic portal circulation (<xref ref-type="fig" rid="fig1-1538574413485646">Figure 1</xref>), which may occur due to overflow of the sclerosant into the portal circulation leading to a transient rise in hepatic enzymes and bilirubin. Third, although none of the patients were actively bleeding, there may have been prior gastrointestinal blood that elevates the bilirubin. Finally, the transient bilirubin rise may be due to transient hepatic portovenous engorgement and associated transient hepatic congestion leading to increased liver enzymes/liver function parameters. Unfortunately, due to the retrospective nature of this study, we have no definitive explanation. It should be noted that <xref ref-type="fig" rid="fig1-1538574413485646">Figure 1</xref> demonstrates an unusually significant embolization of the portal vein from an imaging standpoint (asymptomatic but with transient increase in liver enzymes and bilirubin), and that most BRTO procedures do not have this extent of imaging evidence of portal vein embolization.</p>
<fig id="fig1-1538574413485646" position="float">
<label>Figure 1.</label>
<caption>
<p>Fluoroscopic spot image after deflating the balloon occlusion catheter (dashed arrow) which is placed coaxially through a venous sheath (dotted arrow). The sclerosant is seen in place in the gastrorenal shunt (lower hollow arrow) and gastric varices (upper hollow arrow). However, sclerosant is also seen in the intrahepatic branches of the left portal vein (solid white arrows). This is a case of portal vein embolization by the sclerosant. It is of no clinical significance and is an incidental finding.</p>
</caption>
<graphic xlink:href="10.1177_1538574413485646-fig1.tif"/>
</fig>
<p>A common discussion in the BRTO literature is the ability of the BRTO procedure to divert portal blood flow toward liver and thus preserving, if not improving, hepatic function.<sup>
<xref ref-type="bibr" rid="bibr16-1538574413485646">16</xref>,<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>,<xref ref-type="bibr" rid="bibr21-1538574413485646">21</xref>,<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr24-1538574413485646">24</xref>,<xref ref-type="bibr" rid="bibr33-1538574413485646">33</xref>
</sup> Miyamoto et al showed a 50% increase in average (230 mL/min) of portal flow after BRTO (from 440 to 670 mL/min).<sup>
<xref ref-type="bibr" rid="bibr21-1538574413485646">21</xref>
</sup> The increased portal flow potentially has an advantage and a disadvantage. The disadvantage is that it adds to the portal hypertension that is reflected by the high incidence of aggravation of esophageal varices and portal hypertensive gastropathy after BRTO.<sup>
<xref ref-type="bibr" rid="bibr14-1538574413485646">14</xref>,<xref ref-type="bibr" rid="bibr16-1538574413485646">16</xref>,<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>
<xref ref-type="bibr" rid="bibr21-1538574413485646"/>–<xref ref-type="bibr" rid="bibr22-1538574413485646">22</xref>,<xref ref-type="bibr" rid="bibr25-1538574413485646">25</xref>,<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>,<xref ref-type="bibr" rid="bibr32-1538574413485646">32</xref>
<xref ref-type="bibr" rid="bibr33-1538574413485646"/>
<xref ref-type="bibr" rid="bibr34-1538574413485646"/>–<xref ref-type="bibr" rid="bibr35-1538574413485646">35</xref>
</sup> In this study, we did not encounter any variceal bleeding. However, the advantage of BRTO is that it directs more portal flow toward the liver and potentially improves, if not preserves, hepatic function.<sup>
<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>,<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>,<xref ref-type="bibr" rid="bibr33-1538574413485646">33</xref>
</sup>
</p>
<p>However, certain patients have preserved or improved hepatic function, and others are unresponsive to the increased flow.<sup>
<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>,<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>
</sup> Furthermore, the majority of patients with improved hepatic function return to baseline within 6 to 9 months (the improvement of hepatic function is transient).<sup>
<xref ref-type="bibr" rid="bibr21-1538574413485646">21</xref>,<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr24-1538574413485646">24</xref>
</sup> The theories to explain this include: (1) gradual reduction in the hepatic vascular resistance of the liver, (2) development of portosystemic shunts particularly the esophagus azygos route (esophageal varices) that autodecompress the portal system yet again,<sup>
<xref ref-type="bibr" rid="bibr24-1538574413485646">24</xref>
</sup> and/or (3) natural progression of underlying liver disease. The hypothesis behind why certain patients do not respond to the portal flow diversion is that certain patients have irreversible hepatic disease/damage that does not respond to increased portal blood flow.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>
</sup> However, these studies neglect the fact that there is another major component of this blood flow diversion theory that has to be taken into account. That is, most probably, not all gastrorenal or gastrosplenorenal shunts have the same throughput (blood flow) that can potentially be diverted toward the portal circulation when they are blocked/sclerosed. Large throughput gastrorenal shunts, when thrombosed by the BRTO procedure, would potentially divert large volumes of portal blood flow, which otherwise would be diverted from the portal circulation and liver, back into the portal circulation causing a significant increase in portal hypertension and potentially improving hepatic function. Lesser gastrorenal shunts with lesser throughput would have a lesser effect on the portal circulation, portal hypertension, and/or potentially improved hepatic function.</p>
<p>Patients with prior TIPS or undergoing a TIPS procedure and a BRTO procedure (N = 9 in this study) were excluded in this study, because we wanted to obtain uniformity in the population being studied, particularly when the hypotheses for changes in hepatic function are based on shunting portal blood flow to or from the liver. However, the study is still limited mostly due to its retrospective nature and relatively small sample size. Conversely, 26 patients are, a relatively large number of patients, given the clinical setting of gastric varices treated by BRTO. Due to the current study’s retrospective nature, the sampling is not uniform and incomplete. Three (10%, N = 3 of 31) of the potential patients for this study did not have post-BRTO laboratory values and were excluded from the study. In addition, we cannot verify our hypotheses for the increased bilirubin in the early post-BRTO period (portal vein embolization and/or hemolysis), for example. One additional critique of this study is that it has a relatively short laboratory follow-up (up to 6 months post-BRTO). However, the vast majority of patients with ascites, hydrothorax, acute hepatic dysfunction occur within 30 days from the BRTO procedure.<sup>
<xref ref-type="bibr" rid="bibr20-1538574413485646">20</xref>,<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>
<xref ref-type="bibr" rid="bibr24-1538574413485646"/>
<xref ref-type="bibr" rid="bibr25-1538574413485646"/>
<xref ref-type="bibr" rid="bibr26-1538574413485646"/>
<xref ref-type="bibr" rid="bibr27-1538574413485646"/>–<xref ref-type="bibr" rid="bibr28-1538574413485646">28</xref>,<xref ref-type="bibr" rid="bibr31-1538574413485646">31</xref>,<xref ref-type="bibr" rid="bibr32-1538574413485646">32</xref>
</sup> Furthermore, all the reports of improved hepatic function post-BRTO show that it occurs within the first 6 months after the BRTO and then hepatic function, if initially improved, returns to pre-BRTO baseline levels after 6 months from the BRTO procedure.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413485646">23</xref>,<xref ref-type="bibr" rid="bibr29-1538574413485646">29</xref>
</sup>
</p>
<p>In conclusion, there is a statistically significant but transient rise in the total serum bilirubin in the immediate (within days) post-BRTO period that has no effect on the MELD and C-P scores. The BRTO of gastric varices has a positive effect on the objective laboratory values of liver function tests, particularly the total serum bilirubin, the INR, and the serum albumin, and this is reflected by the improved MELD score circa 4 months post-BRTO. However, there is an increased incidence (31% of patients) of ascites with or without hydrothorax post-BRTO, which masks these improved laboratory values rendering the C-P score not significantly changed circa 1.5 and 4 months post-BRTO. As a result, the MELD score may be a better indicator of change in the hepatic reserve after BRTO compared to the C-P score. Worsening transudative complications in the presence of improved synthetic function suggests that these transudative complications are probably portal pressure driven (oncotic pathogenesis) and less related to hepatocyte dysfunction.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1538574413485646">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1538574413485646">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1538574413485646">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamath</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WR</given-names>
</name>
</person-group>. <article-title>The Model for end-stage liver disease (MELD)</article-title>. <source>Hepatology</source>. <year>2007</year>;<volume>45</volume>(<issue>3</issue>):<fpage>797</fpage>–<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr2-1538574413485646">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamath</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Malinchoc</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A model to predict survival in patients with end-stage liver disease</article-title>. <source>Hepatology</source>. <year>2001</year>;<volume>33</volume>(<issue>2</issue>):<fpage>464</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr3-1538574413485646">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montgomery</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferral</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Postoak</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures</article-title>. <source>Cardiovasc Intervent Radiol</source>. <year>2005</year>;<volume>28</volume>(<issue>3</issue>):<fpage>307</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr4-1538574413485646">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferral</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>NH</given-names>
</name>
</person-group>. <article-title>Selection criteria for patients undergoing transjugular intrahepatic portosystemic shunt procedures: current status</article-title>. <source>J Vasc Interv Radiol</source>. <year>2005</year>;<volume>16</volume>(<issue>4</issue>):<fpage>449</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr5-1538574413485646">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saad</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Darwish</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Waldman</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome</article-title>. <source>J Vasc Interv Radiol</source>. <year>2010</year>;<volume>21</volume>(<issue>2</issue>):<fpage>218</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr6-1538574413485646">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferral</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gamboa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Postoak</surname>
<given-names>DW</given-names>
</name>
<etal/>
</person-group>. <article-title>Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score</article-title>. <source>Radiology</source>. <year>2004</year>;<volume>231</volume>(<issue>1</issue>):<fpage>231</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr7-1538574413485646">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferral</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Speeg</surname>
<given-names>KV</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures</article-title>. <source>J Vasc Interv Radiol</source>. <year>2002</year>;<volume>13</volume>(<issue>11</issue>):<fpage>1103</fpage>–<lpage>1108</lpage>.</citation>
</ref>
<ref id="bibr8-1538574413485646">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marroco-Trischitta</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Kahlberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Astore</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tshiombo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mascia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chiesa</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Outcome in cirrhotic patients after elective surgical repair of infrarenal aortic aneurysm</article-title>. <source>J Vasc Surg</source>. <year>2011</year>;<volume>53</volume>(<issue>4</issue>):<fpage>906</fpage>–<lpage>911</lpage>.</citation>
</ref>
<ref id="bibr9-1538574413485646">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhanasekaran</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kooby</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Staley</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Kauh</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study</article-title>. <source>HPB (Oxford)</source>. <year>2010</year>;<volume>12</volume>(<issue>3</issue>):<fpage>174</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr10-1538574413485646">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Sinn</surname>
<given-names>DH</given-names>
</name>
<etal/>
</person-group>. <article-title>Mortality after surgery in patients with liver cirrhosis: comparison of Child-Turcotte-Pugh, MELD, and MELDNa score</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2011</year>;<volume>23</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr11-1538574413485646">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanagawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kouyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gotoh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration</article-title>. <source>J Gastroenterol Hepatol</source>. <year>1996</year>;<volume>11</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr12-1538574413485646">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyosue</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Okino</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>Transcatheter oliteration of gastric varices. Part-1. Anatomic classification</article-title>. <source>Radiographics</source>. <year>2003</year>;<volume>23</volume>(<issue>4</issue>):<fpage>911</fpage>–<lpage>920</lpage>.</citation>
</ref>
<ref id="bibr13-1538574413485646">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyosue</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Okino</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Transcatheter oliteration of gastric varices: part-2. Strategy and techniques based on hemodynamic features</article-title>. <source>Radiographics</source>. <year>2003</year>;<volume>23</volume>(<issue>4</issue>):<fpage>921</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr14-1538574413485646">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kamada</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage</article-title>. <source>AJR Am J Roentgenol</source>. <year>2002</year>;<volume>178</volume>(<issue>5</issue>):<fpage>1167</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr15-1538574413485646">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ninoi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaminou</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>TIPS versus transcatheter sclerotherapy for gatsric varices</article-title>. <source>AJR Am J Roentgenol</source>. <year>2004</year>;<volume>183</volume>(<issue>2</issue>):<fpage>369</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr16-1538574413485646">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ninoi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kaminou</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients</article-title>. <source>AJR Am J Roentgenol</source>. <year>2005</year>;<volume>184</volume>(<issue>4</issue>):<fpage>1340</fpage>–<lpage>1346</lpage>.</citation>
</ref>
<ref id="bibr17-1538574413485646">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikamori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kuniyoshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shibuya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takase</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Combination treatment of transjugular retrograde obliteration and endoscopic embolization for portosystemic encephalopathy with esophageal varices</article-title>. <source>Hepatogastroenterology</source>. <year>2004</year>;<volume>51</volume>(<issue>59</issue>):<fpage>1379</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr18-1538574413485646">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikamori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kuniyoshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shibuya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takase</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Eight years of experience with transjugular retrograde obliteration for gastric varices with gastrorenal shunts</article-title>. <source>Surgery</source>. <year>2000</year>;<volume>129</volume>(<issue>4</issue>):<fpage>414</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr19-1538574413485646">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saad</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Kalagher</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of transjugular intrahepatic portosystemic shunt (TIPS) placement on renal function: a 7-year, single center experience</article-title>. <source>JVIR J Vasc Interv Radiol</source>. <year>2010</year>;<volume>21</volume>(<issue>9</issue>):<fpage>1370</fpage>–<lpage>1376</lpage>.</citation>
</ref>
<ref id="bibr20-1538574413485646">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>IH</given-names>
</name>
<etal/>
</person-group>. <article-title>Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients</article-title>. <source>AJR Am J Roentgenol</source>. <year>2007</year>;<volume>189</volume>(<issue>6</issue>):<fpage>W365</fpage>–<lpage>W372</lpage>.</citation>
</ref>
<ref id="bibr21-1538574413485646">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Oho</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kumamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toyonaga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sata</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2003</year>;<volume>18</volume>(<issue>8</issue>):<fpage>934</fpage>–<lpage>942</lpage>.</citation>
</ref>
<ref id="bibr22-1538574413485646">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hamamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices</article-title>. <source>Am J Gastroenterol</source>. <year>1999</year>;<volume>94</volume>(<issue>3</issue>):<fpage>643</fpage>–<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr23-1538574413485646">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toyonaga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2010</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1129</fpage>–<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr24-1538574413485646">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikamori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kuniyoshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shibuya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takase</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Eight years of experience with transjugular retrograde obliteration for gastric varices with gastrorenal shunts</article-title>. <source>Surgery</source>. <year>2000</year>;<volume>129</volume>(<issue>4</issue>):<fpage>414</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr25-1538574413485646">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikamori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kuniyoshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takase</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Gastric varices with gastrorenal shunt: combined therapy using transjugular retrograde obliteration and partial splenic embolization</article-title>. <source>AJR Am J Roengenol</source>. <year>2008</year>;<volume>191</volume>(<issue>2</issue>):<fpage>555</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr26-1538574413485646">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonomura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kishi</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Balloon-occluded retrograde transvenous obliteration for gastric varices: a feasibility study</article-title>. <source>Cardiovasc Intervent Radiol</source>. <year>1998</year>;<volume>21</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr27-1538574413485646">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimoda</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Short-term complications of balloon-occluded retrograde transvenous obliteration of gastric varices in patients with portal hypertension: effects of obliteration of major portosystemic shunts</article-title>. <source>Abdom Imaging</source> <year>2005</year>;<volume>30</volume>(<issue>3</issue>):<fpage>306</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr28-1538574413485646">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group>. <article-title>Therapeutic efficacy of balloon-occluded retrograde transvenous obliteration in patients with gastric variceal bleeding</article-title>. <source>Korean J Gastroenterol</source>. <year>2006</year>;<volume>47</volume>(<issue>5</issue>):<fpage>370</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr29-1538574413485646">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirota</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sugimura</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy</article-title>. <source>JVIR J Vasc Interv Radiol</source>. <year>2001</year>;<volume>12</volume>(<issue>3</issue>):<fpage>327</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr30-1538574413485646">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabri</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Swee</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Turba</surname>
<given-names>UC</given-names>
</name>
<etal/>
</person-group>. <article-title>Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration (BRTO) utilizing sodium tetradecyl sulfate foam</article-title>. <source>JVIR J Vasc Interv Radiol</source>. <year>2011</year>;<volume>22</volume>(<issue>3</issue>):<fpage>309</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr31-1538574413485646">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chikamori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kuniyoshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takase</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Gastric varices with gastrorenal shunt: combined therapy using transjugular retrograde obliteration and partial splenic embolization</article-title>. <source>AJR Am J Roengenol</source>. <year>2008</year>;<volume>191</volume>(<issue>2</issue>):<fpage>555</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr32-1538574413485646">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H-C</given-names>
</name>
<name>
<surname>Jae</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>The prevalence, risk factors, and clinical outcome of balloon rupture in balloon-occluded retrograde transvenous obliteration of gastric varices</article-title>. <source>JVIR J Vasc Intervent Radiol</source>. <year>2010</year>;<volume>21</volume>(<issue>4</issue>):<fpage>503</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr33-1538574413485646">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akahoshi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hashizume</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tomikawa</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience</article-title>. <source>Gastroenterology</source>. <year>2008</year>;<volume>23</volume>(<issue>11</issue>):<fpage>1702</fpage>–<lpage>1709</lpage>.</citation>
</ref>
<ref id="bibr34-1538574413485646">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirota</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sako</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kono</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Retrograde transvenous obliteration of gastric varices</article-title>. <source>Radiology</source>. <year>1999</year>;<volume>211</volume>(<issue>2</issue>):<fpage>349</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr35-1538574413485646">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamagami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hirota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshimatsu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Infusion of 50% glucose solution before injection of ethanolamine oleate during balloon-occluded retrograde transvenous obliteration</article-title>. <source>Australas Radiol</source>. <year>2007</year>;<volume>51</volume>(<issue>4</issue>):<fpage>334</fpage>–<lpage>338</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>